Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Rattachement africain : it, gr, es, fr, us, ro, ca, cz, au, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: In the CheckMate 238 trial, patients with resected stage IIIB-C or stage IV melanoma who were treated with nivolumab had longer recurrence-free survival than those who received ipilimumab. Data were needed on longer-term survival. METHODS: We randomly assigned patients in a 1:1 ratio to receive an intravenous infusion of nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks) or ipilimumab (at a dose of 10 mg per kilogram every 3 weeks for four doses, then every 12 weeks) for up to 1 year or until disease recurrence or the occurrence of unacceptable toxic effects. Randomization was stratified according to disease stage and status with respect to programmed cell death ligand 1. The primary end point was recurrence-free survival; secondary end points included overall and distant metastasis-free survival and safety. RESULTS: At a minimum follow-up of nearly 9 years (107 months), the median duration of recurrence-free survival was 61.1 months with nivolumab and 24.2 months with ipilimumab (hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.63 to 0.90); 9-year recurrence-free survival was 44% and 37%, respectively. The median duration of distant metastasis-free survival in patients with stage III melanoma was more than 9 years with nivolumab and 83.8 months with ipilimumab, with 9-year survival of 54% and 48%, respectively (hazard ratio for distant metastasis or death, 0.81; 95% CI, 0.65 to 1.00). The median overall survival was more than 9 years in both trial groups, with 9-year survival of 69% in the nivolumab group and 65% in the ipilimumab group (hazard ratio for death, 0.88; 95.03% CI, 0.69 to 1.11). The rates of death from melanoma at 9 years were 26% with nivolumab and 30% with ipilimumab (hazard ratio, 0.87; 95% CI, 0.67 to 1.13). Subsequent systemic therapy was administered to fewer patients in the nivolumab group than in the ipilimumab group (37.3% vs. 44.6%). No new late adverse events were reported. CONCLUSIONS: The 9-year final data support a sustained finding of longer recurrence-free survival with nivolumab than with ipilimumab. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 238 ClinicalTrials.gov number, NCT02388906; Eudra-CT number, 2014-002351-26.).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Nivolumab for Resected Stage III or IV Melanoma at 9 Years
- Date Crossref
- 22/01/2026
- Éditeur
- Massachusetts Medical Society
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" pays non établi dans la noticeÉtablissement de santé
-
Fondazione IRCCS Istituto Nazionale dei Tumori pays non établi dans la noticeÉtablissement de santé
-
Ospedale Papa Giovanni XXIII pays non établi dans la noticeÉtablissement de santé
-
National and Kapodistrian University of Athens pays non établi dans la noticeUniversité ou école supérieure
-
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer pays non établi dans la noticeStructure de recherche
-
Hospices Civils de Lyon pays non établi dans la noticeÉtablissement de santé
-
Texas Oncology pays non établi dans la noticeStructure de recherche
-
University of Medicine and Pharmacy of Craiova pays non établi dans la noticeUniversité ou école supérieure
-
University of Craiova pays non établi dans la noticeUniversité ou école supérieure
-
Aix-Marseille Université pays non établi dans la noticeUniversité ou école supérieure
-
Assistance Publique Hôpitaux de Marseille pays non établi dans la noticeÉtablissement de santé
-
Istituto Oncologico Veneto pays non établi dans la noticeÉtablissement de santé
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Fondazione IRCCS Istituto Nazionale dei Tumori et Ospedale Papa Giovanni XXIII, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.